Skip to main content

Table 2 Characteristics of included studies

From: Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

Intervention Indication No. of studies Parallel/crossover Maximum dose Comparator Treatment length (weeks)
Dronabinol Chronic pain 16 9/7 8–129.6 mg. Most common: 2.5–15 mg (n = 11) Placebo Acute to 156. Most common: acute (n = 5)
1 0/1 20 mg Active 8
Spasticity 6 4/2 2.5–60 mg Placebo  < 1 week to 144. Most common: 4 (n = 2)
Nausea, vomiting, loss of appetite 14 6/8 5–129.6 mg. Most common: 5–20 mg (n = 12) Placebo Acute to 6. Most common: 1–5 days (n = 8)
6 3/3 5–100 mg. Most common: 5–10 (n = 3) Active Acute to 9.8. Most common: acute (n = 4)
ALS 1 0/1 10 mg Placebo 2
Dystonia 1 0/1 15 mg Placebo 8
Glaucoma 1 0/1 5 mg Placebo Acute
IBS 2 1/1 2.5–10 mg Placebo Acute
MS 3 3/0 25–8 mg Placebo 14 (n = 2), 156 (n = 1)
Anorexia Nervosa 1 0/1 5 mg Placebo 4
1 0/1 30 mg Active 2
Anxiety 8 3/5 5–30 mg. Most common: 10 mg (n = 6) Placebo Acute to 7.3. Most common: acute (n = 6)
2 1/1 30–50 mg Active Acute to 6
Depression 8 4/4 5–30 mg. Most common: 5–10 mg (n = 7) Placebo  < 1 week to 156. Most common: less than 1 week (n = 4)
2 1/1 30–50 mg Active Acute and 6
Dementia 3 1/2 1.5–5 mg Placebo 1 to 6
PTSD 1 1/0 7.5 mg Placebo Acute
Psychosis/schizophrenia 1 0/1 2.5–5 mg Placebo Acute
Sleep 8 4/4 2.5–129.6 mg. Most common: 10 mg (n = 3), 129.6 mg (n = 2) Placebo  < 1 week to 14. Most common: less than 1 week to 2 (n = 5)
2 1/1 30 mg Active 2 and 6
SUDs 4 1/3 5–40 mg Placebo Acute (n = 2), < 1 week and 8
1 1/0 30 mg Active 6
Tourette 2 1/1 5–10 mg Placebo Acute and 6
Nabilone Chronic pain 9 6/3 0.25–4 mg. Most common: 2 mg (n = 5) Placebo 4 to 9. Most common: 4 (n = 4)
3 0/3 0.5–2 mg Active 2 to 8
Spasticity 2 0/2 1 mg Placebo 4
Nausea, vomiting, loss of appetite 6 3/3 0.5–6 mg. Most common: 0.5–2 mg (n = 4) Placebo Acute/ < 1 week (n = 3) to 6–8 (n = 3)
11 3/8 1–8 mg. Most common: 1–4 mg (n = 10) Active Acute to 1
Huntington 1 0/1 1 and 2 mg Placebo 5
Dystonia 1 0/1 0.03 mg Placebo Acute
Parkinson 2 1/1 0.06 and 2 mg Placebo Acute and 4
Anxiety 8 5/3 1–8 mg Placebo  < 1 week to 10
2 0/2 0.5 and 2 mg Active 6 and 8
Dementia 1 0/1 2 mg Placebo 6
Depression 5 4/1 1–5 mg Placebo Acute to 10. Most common: 4–5 (n = 3)
2 0/2 0.5 and 2 mg Active 6 and 8
PTSD 1 0/1 3 mg Placebo 7
Sleep 7 4/3 1–8 mg. Most common: 1–4 mg (n = 6) Placebo  < 1 week to 8
2 0/2 0.5, 1 and 2 mg Active 2 and 6
SUDs 3 1/2 2, 6 and 8 mg Placebo  < 1 week (n = 2) and 10
Cannabidiol Chronic pain 1 1/0 20 mg, 30 mg Placebo 12
Nausea, vomiting, loss of appetite 1 1/0 200 mg Placebo 13
Huntington 1 0/1 10 mg Placebo 6
Epilepsy 6 6/0 10–300 mg. Most common: 10–20 mg (n = 4) Placebo 14 (n = 4), 16 and 18
Parkinson 3 2/1 75 and 300 mg Placebo Acute, 6 and 12
Anxiety 11 9/2 400–800 mg. Most common: 300 mg (n = 4), 400 mg (n = 3) Placebo Acute to 12. Most common: acute to < 1 week (n = 5)
Depression 6 6/0 75–400 mg Placebo 1 to 13
Psychosis/schizophrenia 4 3/1 300 mg, 600 mg (n = 2) and 1000 mg Placebo Acute (n = 2) and 6 (n = 2)
1 1/0 800 mg Active 4
Sleep 9 9/0 10–1000 mg. Most common: 10–20 mg (n = 5) Placebo 1 to 14. Most common: 12–14 (n = 5)
SUDs 7 6/2 400–800 mg. Most common doses: 800 mg (n = 5) Placebo Acute to 13. Most common: < 1 week (n = 4)
Nabiximols Chronic pain 20 16/4 10.8–129.6 mg THC: 10–120 mg CBD. Most common: 32.4 mg THC: 30 mg:CBD (n = 7), 129.6 mg THC: 120 mg CBD (n = 5) Placebo 2 to 14. Most common: 5 (n = 6), 12 (n = 4)
Spasticity 14 6/4 8.1–129.6 mg THC: 7.5–120 mg CBD. Most common: 32.4 mg THC: 30 mg:CBD (n = 6), 129.6 mg THC: 120 mg CBD (n = 2) Placebo 2 to 14. Most common: 12 (n = 3), 6 (n = 3), 4 (n = 3)
Nausea, vomiting, loss of appetite 8 6/2 5–129.6 mg THC: 2–120 mg CBD Placebo  < 1 week to 12. Most common: < 1 week (n = 3)
ALS 1 1/0 32.4 mg THC: 30 mg CBD Placebo 6
Chorea Hunington 1 0/1 32.4 mg THC: 30 mg CBD Placebo 12
Dystonia 1 0/1 32.4 mg THC: 30 mg CBD Placebo 12
Glaucoma 1 0/1 CBD: THC (1:21). 20, 40 mg Placebo Acute
MS 5 4/1 30–129.6 mg THC: 10.8–120 mg CBD Placebo 2 to 14. Most common: 14 (n = 2)
ADHD 1 1/0 37.8 mg THC: 35 mg CBD Placebo 6
Depression 8 5/3 32.4–129.6 mg THC: 30–120 mg CBD. Most common: 32.4 mg THC: 30 mg:CBD (n = 2) Placebo  < 1 week to 12. Most common: 12 (n = 3)
Anxiety 6 3/3 30–129.6 mg THC: 10.8–120 mg CBD Placebo 3 to 12. Most common: 12 (n = 2)
Sleep 22 18/4 16.2–129.6 mg THC: 15–120 mg CBD. Most common: 32.4 mg THC: 30 mg:CBD (n = 6), 129.6 mg THC: 120 mg CBD (n = 4) Placebo  < 1 week to 14. Most common: 5 (n = 6), 12 (n = 4)
SUDs 4 3/1 64.8–113.4 mg THC: 60–105 mg CBD Placebo  < 1 week to 12. Most common: 12 (n = 2)